Glycosphingolipids as Therapeutic Targets and Biomarkers of Lupus Nephritis
Technical Report,30 Sep 2016,29 Sep 2017
MEDICAL UNIV OF SOUTH CAROLINA CHARLESTON United States
Pagination or Media Count:
All urine and serum samples for the full biomarker study in lupus nephritis patients that have responded and failed therapy have been identified and collected. Prior to beginning the full study, we testedstreamlined the workflow and identified putative lipidprotein candidates in a pilot study among the full study patients that had flare and non-flare urine samples. We also collected all the renal biopsies and are currently performing the MALDIFTICR analyses for correlating renal lipid expression with clinical disease measures. We completed the backcrossing of the Neu1 knockout from the C57BL6 mice to the lupus mouse strain B6.SLE123 and are breeding to obtain sufficient numbers of mice for the genetic study analyzing the effects of reducing NEU1 levels on disease development. To identify mechanisms by which NEU-mediated GSL catabolism impacts renal function and dysfunction in lupus, additional studies were performed on mesangial cells from mice in our proposed studies. Results include demonstrating that 1 that NEU activity mediates IL-6 production in mesangial cells, 2 NEU13 expression co-localizes with renal IgG deposition, and 3 mesangial cells from Neu1 knockout mice have reduced NEU activity and produce significantly reduced levels of IL-6 compared to Neu wild-type.
- Medicine and Medical Research